Current therapies for Pseudomonas Aeruginosa Infection


Key R & D Program of Ministry of Science and Technology(2020YFA090900), Research Instrument and Equipment Development Project of Chinese Academy of Sciences (YJKYYQ20200033), National Natural Science Foundation of China (21774117), and Shenzhen Science Technology and Innovation Commission (KQTD2015033117210153)

Ethical statement:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials

    Pseudomonas aeruginosa has strong intrinsic antibiotic drug resistance and the ability to acquire further resistance mechanisms to multiple antibiotics. Therefore, for patients with Pseudomonas aeruginosa infection, the emergence of multidrug-resistant Pseudomonas aeruginosa often means that the efficacy of antibiotics has deteriorated or even completely ineffective. The development of new antibiotics takes a long time and is costly. Therefore, looking for new antibacterial drugs to replace antibiotics, finding new drug carriers, and new treatment methods to increase the activity of antibacterial drugs against multidrug resistant Pseudomonas aeruginosa infection treatment is of great significance. In this paper, some basic laboratory and clinical studies about using organic acids, antimicrobial peptides, nanoparticles, bacteriophages, hydrogels, bacterias in the treatment of Pseudomonas aeruginosa infection were reviewed and summarized to provide a reference for the treatment of multi-antibiotics resistant Pseudomonas aeruginosa infection.

    Cited by
Get Citation

JIN Fan, GAO Yanmei, HUANG Yajia, et al. Current therapies for Pseudomonas Aeruginosa Infection[J]. Journal of Integration Technology,2021,10(4):50-66

Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Received:
  • Revised:
  • Adopted:
  • Online: July 26,2021
  • Published: